| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 05.11. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Alpha Teknova Q3 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 05.11. | Alpha Teknova GAAP EPS of -$0.06 beats by $0.01, revenue of $12.7M beats by $0.93M | 1 | Seeking Alpha | ||
| 04.11. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.10. | Full-Year Revenue Guidance Hike Drove Alpha Teknova (TKNO) Higher | 3 | Insider Monkey | ||
| 22.10. | Alpha Teknova, Inc.: Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026 | 4 | GlobeNewswire (USA) | ||
| 21.10. | Alpha Teknova, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.10. | Morning Market Movers: Robin Energy, Olenox Industries, Ashford Hospitality Trust, Alpha Teknova See Big Swings | 706 | AFX News | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 21.10. | Alpha Teknova prices $40M stock offering at $5 per share | 2 | Seeking Alpha | ||
| 21.10. | Alpha Teknova Shares Sink 23% After Hours: Here's Why | 3 | Benzinga.com | ||
| 21.10. | Alpha Teknova prices $40 million stock offering at $5/share | 3 | Investing.com | ||
| 20.10. | Alpha Teknova-Aktie bricht nach Ankündigung einer Kapitalerhöhung ein | 1 | Investing.com Deutsch | ||
| 20.10. | Alpha Teknova launches public offering of common stock | 1 | Investing.com | ||
| 20.10. | Teknova reports preliminary Q3 revenue of $12.5-12.7 million | 1 | Investing.com | ||
| 20.10. | Alpha Teknova reports Preliminary Q3 results | 1 | Seeking Alpha | ||
| 02.10. | Alpha Teknova, Inc.: Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze Cryopreservation System | 439 | GlobeNewswire (Europe) | HOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), and Pluristyx, Inc. ("Pluristyx"), today announced that Pluristyx is completing a Type II Drug... ► Artikel lesen | |
| 24.09. | Biotech Stocks At 52-Week Highs - Alpha Teknova, Moderna, AtriCure, Illumina | 1.385 | AFX News | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 23, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.Alpha... ► Artikel lesen | |
| 17.09. | Jefferies startet Coverage für Alpha Teknova mit Kaufempfehlung und verweist auf Wachstumsausblick | 2 | Investing.com Deutsch | ||
| 17.09. | Jefferies initiates Alpha Teknova stock with buy on growth outlook | 1 | Investing.com | ||
| 16.09. | Teknova launches Fill-Tek dispensing system for custom reagents | 1 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,710 | -3,21 % | Biofrontera: Liquidität unter Druck - was jetzt zählt | ||
| INOVIO PHARMACEUTICALS | 1,509 | -2,90 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| CLINUVEL | 4,242 | -2,12 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| INFLARX | 0,972 | -3,67 % | InflaRx im Check: Izicopan rückt vor, der Chart bleibt unter Druck | ||
| INTELLIA THERAPEUTICS | 9,110 | +4,83 % | Intellia Therapeutics (NDQ:NTLA): The World's First Commercial CRISPR Franchise Could Be Closer Than Investors Think | ||
| DEFENCE THERAPEUTICS | 0,161 | +2,22 % | Defence Therapeutics Inc.: Defence Therapeutics Invites Shareholders to Its December 10, 2026, Annual General Meeting and 2027 Strategic Update | Montreal, Quebec--(Newsfile Corp. - November 16, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 1,570 | +0,32 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,666 | +0,15 % | BioCryst presents real-world data on ORLADEYO at ACAAI meeting | ||
| CARDIOL THERAPEUTICS | 0,800 | -0,50 % | Bayer, Cardiol Therapeutics, Novartis - Biotech-Aktien und Pharmariesen im Wettlauf ums Herz | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Kardiologie gehört zu den spannendsten Feldern der Pharmabranche. Vier Tage in Chicago haben gezeigt, wie viel Bewegung in der Herzmedizin... ► Artikel lesen | |
| GERON | 0,844 | +1,37 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IBIO | 0,700 | -4,70 % | iBio reports weight loss data from obesity drug candidate study | ||
| IMMUNITYBIO | 5,630 | -6,01 % | ImmunityBio (IBRX) is Declining For 4 Days Now. What's Triggering the Selloff? | ||
| ARBUTUS BIOPHARMA | 3,660 | -1,61 % | Arbutus Biopharma: FDA hebt klinischen Stopp auf - wie weit trägt die Aktie? | ||
| IMMATICS | 5,315 | -2,03 % | Jefferies reiterates Immatics stock Buy rating after conference | ||
| CELLECTAR BIOSCIENCES | 0,850 | -3,73 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen |